Jae Park, MD is an Attending Physician and Chief of Cellular Therapy Service, and a Director of Adult Acute Lymphoblastic Leukemia Program at Memorial Sloan Kettering Cancer Center. Dr. Park has written over 100 peer-reviewed articles appearing in New England Journal of Medicine, Lancet, Nature Medicine, Science Translational Medicine, Blood, Cancer Discovery and Journal of Clinical Oncology focused on developing effective and safe targeted and immunotherapies and conducting translational studies. To this end, he has successfully conducted over 15 investigator-initiated therapeutic trials in the field of hematologic malignancies and cellular therapy with grant supports from ASH, LLS, ASCO, AACR and NCCN. He is widely recognized as one of the world experts in the field of CAR T cell therapies and ALL and is the leading PI of clinical trials in patients with ALL and CLL/NHL using CAR T, NK cell therapies, BiTEs, IDCs, targeted agents, and immunomodulators.
Jae Park MD
Sloan Kettering Institute for Cancer Research
New York, New York
United States
Project Title
IL7 receptor-targeted CAR T-cell Therapy for T-Acute Lymphoblastic Leukemia (T-ALL) Developing novel therapeutic approaches for classical and variant hairy cell leukemia
Program
Academic Clinical Trials Program (ACT)
Hairy Cell Leukemia Research Initiative